Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have proven clinical utility across various cancer types. Several independently developed PD-L1 immunohistochemical (IHC) predictive assays are commercially available. Published studies using the VENTANA PD-L1 (SP263)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawson, Nicola L., Dix, Carly I., Scorer, Paul W., Stubbs, Christopher J., Wong, Edmond, Hutchinson, Liam, McCall, Eileen J., Schimpl, Marianne, DeVries, Emma, Walker, Jill, Williams, Gareth H., Hunt, James, Barker, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075905/
https://www.ncbi.nlm.nih.gov/pubmed/31558782
http://dx.doi.org/10.1038/s41379-019-0372-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075905/
https://www.ncbi.nlm.nih.gov/pubmed/31558782
http://dx.doi.org/10.1038/s41379-019-0372-z

Ejemplares similares